Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant-Reference-Cited by-同舟云学术

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant

Published:2012-01-03 Issue:6 Volume:53 Page:1130-1136
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lane Andrew A.¹²³,Armand Philippe¹³,Feng Yang⁴³,Neuberg Donna S.⁴³,Abramson Jeremy S.²³,Brown Jennifer R.¹³,Fisher David C.¹³,LaCasce Ann S.¹³,Jacobsen Eric D.¹³,McAfee Steven L.²³,Spitzer Thomas R.²³,Freedman Arnold S.¹³,Chen Yi-Bin¹²³

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

2. Massachusetts General Hospital Cancer Center, Boston, MA, USA

3. Harvard Medical School Boston, MA, USA

4. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.645208

Reference27 articles.

1. Autologous and Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma

2. Stem Cell Transplantation for Non-Hodgkin's Lymphoma

3. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. 2010. Available from: http://www.cibmtr.org

4. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies

5. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic Cell Transplantation for Hodgkin Lymphoma;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

2. BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia;Journal of Clinical Medicine;2023-03-19

3. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial;The Lancet Haematology;2023-01

4. Engraftment Syndrome and Peri-engraftment Respiratory Distress;Pulmonary and Critical Care Considerations of Hematopoietic Stem Cell Transplantation;2023

5. Pulmonary Complications After Pediatric Stem Cell Transplant;Frontiers in Oncology;2021-10-13